Bayer Pharmaceuticals has launched a new platform called Calantic Digital Solutions (CDS), which will provide access to digital applications, including AI-enabled programs for medical imaging. This platform offers tools that assist radiologists and their teams in prioritization, lesion detection, quantification, and productivity. By expanding their comprehensive portfolio, Bayer aims to support healthcare professionals throughout the entire patient treatment process, from diagnosis to treatment.
CDS will include a suite of AI-enabled applications designed to assist radiologists at critical stages in a patient’s treatment. This vendor-neutral platform, hosted on the cloud, offers a growing number of applications that prioritize, detect and quantify lesions, automate routine tasks, improve workflow, and save time for radiologists and their teams. Initially, the focus is on thoracic and neurological diseases such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO), which are associated with stroke. More disease-specific applications will be added in the future.
The demand for AI in medical imaging is driven by the growing prevalence of chronic conditions like cardiovascular disease and cancer. AI can accelerate diagnosis, increase throughput of radiological examinations, and help manage the workload of radiologists and their teams. This is crucial as burn-out among radiologists is prevalent due to time pressure and high workload. Additionally, there is a shortage of trained radiologists, and long hours of overtime contribute to a higher rate of diagnostic errors.
Bayer Pharmaceuticals’ new CDS platform offers AI-enabled applications to support radiologists and their teams in medical imaging. This initiative aims to improve diagnosis speed and accuracy, manage workloads, and provide optimal patient care. With a commitment to innovation and excellence, Bayer continues to advance in the radiology market through research, development, and the use of digital technologies.
The whytry.ai article you just read is a brief synopsis; the original article can be found here: Read the Full Article…
